New Studies Show Novo Nordisk’s Combination Insulin Reduces Hypoglycemia


A study released by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress in Dubai has found that the combination insulin degludec/insulin aspart, currently being developed, significantly reduced hypoglycemia in type 1 diabetes and type 2 diabetes patients. 

In the study, insulin degludec/insulin aspart reduced the overall occurrence of hypoglycemia during the day as well as at night (occurring between 23:00 and 05:59). The study found that type 2 diabetes patients using Insulin degludec/insulin aspart reduced rates of hypoglycemia by 58% compared to biphasic insulin aspart when dosed twice-daily.

Improvements in fasting plasma glucose (FPG) were also seen, with levels significantly lower in the insulin degludec/insulin aspart group vs  biphasic insulin aspart (6.4 vs. 7.5 mmol/l). The study also found that insulin degludec/insulin aspart was well tolerated and provided comparable overall glycemic control to biphasic insulin aspart.
A second study also presented showed that rates of hypoglycemia at night were reduced by 37% in people with type 1 diabetes using once-daily insulin degludec/insulin aspart (with additional rapid-acting mealtime insulin doses for the remaining meals), compared to those using once-daily insulin detemir plus rapid-acting insulin at all main meals.
Insulin degludec/insulin aspart, in development by Novo Nordisk, will, pending approval, be the only soluble insulin combination of ultra-long-acting basal insulin degludec and rapid-acting insulin, insulin aspart. Clinical studies have shown that it provides fasting plasma glucose control with significantly less hypoglycemia compared to premix insulin. 
Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x